Market Cap (In JPY)
18.17 Billion
Revenue (In JPY)
-
Net Income (In JPY)
-2.02 Billion
Avg. Volume
153.68 Thousand
- Currency
- JPY
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 285.0-620.0
- PE
- -8.71
- EPS
- -33.52
- Beta Value
- 1.464
- ISIN
- JP3399690001
- CUSIP
- -
- CIK
- -
- Shares
- 62235679.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Masatsune Okajima
- Employee Count
- -
- Website
- https://www.stemrim.com
- Ipo Date
- 2019-08-09
- Details
- StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.
More Stocks
-
PKBFFPeakBirch Commerce Inc.
PKBFF
-
IGGGFIGG Inc
IGGGF
-
688323
-
300478
-
7897Hokushin Co., Ltd.
7897
-
IXOG
-
JAV
-
7971TOLI Corporation
7971